152 institutions hold shares in Ocular Therapeutix Inc. (OCUL), with 3.33M shares held by insiders accounting for 4.66% while institutional investors hold 58.13% of the company’s shares. The shares outstanding are 62.99M, and float is at 62.65M with Short Float at 7.59%. Institutions hold 55.42% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Opaleye Management Inc. with over 6.51 million shares valued at $134.76 million. The investor’s holdings represent 8.58% of the OCUL Shares outstanding. As of Dec 30, 2020, the second largest holder is Summer Road LLC with 5.62 million shares valued at $116.31 million to account for 7.41% of the shares outstanding. The other top investors are Blackrock Inc. which holds 5.51 million shares representing 7.27% and valued at over $114.1 million, while Vanguard Group, Inc. (The) holds 4.68% of the shares totaling 3.55 million with a market value of $73.48 million.
Ocular Therapeutix Inc. (NASDAQ: OCUL) is -10.58% lower on its value in year-to-date trading and has touched a low of $3.78 and a high of $24.30 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OCUL stock was last observed hovering at around $17.33 in the last trading session, with the day’s gains setting it 1.18% off its average median price target of $27.00 for the next 12 months. It is also 38.3% off the consensus price target high of $30.00 offered by 7 analysts, but current levels are -32.21% lower than the price target low of $14.00 for the same period.
Currently trading at $18.51, the stock is -1.93% and -6.26% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.3 million and changing 6.81% at the moment leaves the stock 46.32% off its SMA200. OCUL registered 150.14% gain for a year compared to 6-month gain of 120.88%. The firm has a 50-day simple moving average (SMA 50) of $18.98 and a 200-day simple moving average (SMA200) of $14.89.
The stock witnessed a -1.17% loss in the last 1 month and extending the period to 3 months gives it a -1.23%, and is 0.93% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.82% over the week and 7.97% over the month.
Ocular Therapeutix Inc. (OCUL) has around 161 employees, a market worth around $1.30B and $12.30M in sales. Distance from 52-week low is 390.33% and -23.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-187.80%).
Ocular Therapeutix Inc. (OCUL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ocular Therapeutix Inc. (OCUL) is a “Overweight”. 7 analysts offering their recommendations for the stock have an average rating of 2.00, where 2 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ocular Therapeutix Inc. is expected to release its quarterly report on 05/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.17 with sales reaching $9.76M over the same period.The EPS is expected to shrink by -21.20% this year, but quarterly earnings will post 453.80% year-over-year. Quarterly sales are estimated to grow 332.60% in year-over-year returns.
Ocular Therapeutix Inc. (OCUL) Insider Activity
A total of 14 insider transactions have happened at Ocular Therapeutix Inc. (OCUL) in the last six months, with sales accounting for 7 and purchases happening 7 times. The most recent transaction is an insider purchase by SUMMER ROAD LLC, the company’s 10% Owner. SEC filings show that SUMMER ROAD LLC bought 437 shares of the company’s common stock on Oct 16 at a price of $10.48 per share for a total of $4580.0. Following the purchase, the insider now owns 5.62 million shares.
Ocular Therapeutix Inc. disclosed in a document filed with the SEC on May 19 that SUMMER ROAD LLC (10% Owner) bought a total of 363,636 shares of the company’s common stock. The trade occurred on May 19 and was made at $5.50 per share for $2.0 million. Following the transaction, the insider now directly holds 5.62 million shares of the OCUL stock.
Still, SEC filings show that on Mar 24, SUMMER ROAD LLC (10% Owner) acquired 35,052 shares at an average price of $4.87 for $0.17 million. The insider now directly holds 5,254,788 shares of Ocular Therapeutix Inc. (OCUL).
Ocular Therapeutix Inc. (OCUL): Who are the competitors?
The company’s main competitors (and peers) include KalVista Pharmaceuticals Inc. (KALV) that is trading 128.40% up over the past 12 months. Anika Therapeutics Inc. (ANIK) is -19.27% down on the 1-year trading charts. Short interest in the company’s stock has fallen -13.68% from the last report on Jan 14, 2021 to stand at a total of 5.4 million short shares sold with a short interest ratio of 6.3.